{"id":55050,"date":"2023-03-21T19:03:37","date_gmt":"2023-03-21T18:03:37","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/global-healthy-living-foundation-association-of-women-in-rheumatology-and-the-aids-institute-to-host-congressional-briefing-on-co-pay-accumulator-programs\/"},"modified":"2023-03-21T19:03:37","modified_gmt":"2023-03-21T18:03:37","slug":"global-healthy-living-foundation-association-of-women-in-rheumatology-and-the-aids-institute-to-host-congressional-briefing-on-co-pay-accumulator-programs","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/global-healthy-living-foundation-association-of-women-in-rheumatology-and-the-aids-institute-to-host-congressional-briefing-on-co-pay-accumulator-programs\/","title":{"rendered":"Global Healthy Living Foundation, Association of Women in Rheumatology, and the AIDS Institute To Host Congressional Briefing on Co-Pay Accumulator Programs"},"content":{"rendered":"
\n

\nIn Cooperation with U.S. Representatives Mariannette Miller-Meeks, MD (R-IA) and Nanette Barrag\u00e1n (D-CA), Event to Review the HELP Copays Act (H.R. 830)<\/b>\n<\/p>\n

UPPER NYACK, N.Y.–(BUSINESS WIRE)–#accumulators<\/a>–The Global Healthy Living Foundation (GHLF)<\/a>, an international, patient-centered, nonprofit organization whose mission is to improve the quality of life for people with chronic illness, in partnership with the Association of Women in Rheumatology and the AIDS Institute, will host on Thursday, March 30, 2023 a Congressional Briefing on copay accumulator programs, the focus of the HELP Copays Act (H.R. 830)<\/a>.\n<\/p>\n

<\/a><\/p>\n

\nCopay accumulator programs <\/b>are used by insurance companies to prevent any charitable copay assistance provided by biopharmaceutical manufacturers from counting toward a patient\u2019s deductible or maximum out-of-pocket expenses, forcing patients to pay for their treatment twice. First, patients pay at the pharmacy with the funds from their copay card. They pay again when the copay card has been depleted and their deductible, supposedly, has not been met. These programs most often impact chronic disease patients taking specialty drugs because those products have the highest out-of-pocket costs, have well-funded out-of-pocket support programs, and lack generic or biosimilar medication substitutions. Patients surprised by these programs, buried in their insurance plan\u2019s fine-print, may find that the medication prescribed by their health care provider is suddenly unaffordable.\n<\/p>\n

\nWhile sixteen states have passed laws to prevent co-pay accumulator programs, federal law is needed to ensure all patients are protected. GHLF research<\/a> demonstrates that these laws do not increase health insurance premiums.\n<\/p>\n

\nMembers of the media are invited to attend this event with advanced RSVP.\n<\/p>\n

\nEvent: <\/b>Congressional Briefing on Copay Accumulator Programs and the HELP Copays Act (H.R. 830)
\n
When:<\/b> Thursday, March 30, 2023, 12:00 to 1:00 p.m. (ET)
\n
Where:<\/b> Capitol Visitors Center, HVC-215\n<\/p>\n

\nSpeakers:<\/b>\n<\/p>\n